Expert Analysis

Update on the Management of HCV and the Complications of Liver Disease

Source: CCO Independent Conference Coverage of the 2009 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Update on the Management of HCV and the Complications of Liver Disease

Faculty:

Adrian M. Di Bisceglie, MD, FACP
Michael P. Manns, MD
Stefan Zeuzem, MD

CREDIT INFORMATION

Release Date: 06/16/09

Expiration Date: 06/15/10

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite new findings on the safety and efficacy of investigational antiviral agents including protease inhibitors and nonnucleoside polymerase inhibitors in patients with chronic HCV infection
Recount the latest results on the optimal treatment duration for HCV-infected patients who experience a slow response to peginterferon/ribavirin therapy
Discuss the relationship between on-treatment hemoglobin decreases, erythropoietin use, and virologic response among patients with chronic HCV infection
Summarize the results of recent clinical trials evaluating new approaches to treating and managing complications associated with advanced liver disease such as hepatic encephalopathy
Articulate the latest findings on the optimal timing of treatment for patients with acute hepatitis C infection

Topics covered include:

SPRINT-1: Boceprevir and Peginterferon alfa-2b/Ribavirin in Treatment-Naive Patients With Genotype 1 HCV
PROVE 3: Telaprevir Plus Peginterferon alfa-2a/Ribavirin in Previously Treated Patients With Genotype 1 HCV
ITMN-191 Plus Peginterferon alfa-2a/Ribavirin in Treatment-Naive Patients Infected With Genotype 1 HCV
SCH 900518 With or Without Ritonavir Plus Peginterferon alfa-2b in Treatment-Naive and Treatment-Experienced Patients With Genotype 1 HCV Infection
Efficacy and Safety of Investigational Nonnucleoside Polymerase Inhibitors
Albinterferon alfa-2b vs Peginterferon alfa-2a in Treatment-Naive Patients With Genotype 1 HCV
48 vs 72 Weeks of Peginterferon alfa-2b/Ribavirin in Slow Responders Infected with Genotype 1 HCV
On-Treatment Hemoglobin Decline, Erythropoietin Use, and Virologic Response to Peginterferon/Ribavirin Therapy
Rifaximin for the Prevention of Recurrent Hepatic Encephalopathy
Immediate vs Delayed Treatment of Acute HCV Infection
High-Dose Ursodeoxycholic Acid Treatment for Nonalcoholic Steatohepatitis

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.